Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Drs Katrina Bramstedt and Ana Iltis discuss the development of QoL assessment tools to help patient-subjects considering reconstructive transplantation.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Proliferation of innovative procedures and treatments in surgery has led to novel and distinct ethical challenges. Medicine can learn from plastic surgeons’ approaches to informed consent and potentially harmful treatments.
AMA J Ethics. 2018;20(4):349-356. doi:
10.1001/journalofethics.2018.20.4.nlit1-1804.
The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves.